PMC5903152_01
Computed tomography (CT) findings at diagnosis. a No metastasis was detected in the mediastinal lymph node. b Right hilar lymphadenopathy was observed. c Gastric cardia (primary lesion). d No metastasis to the para-aortic lymph node was observed.
cro-0011-0143-g01.jpg
PMC5903152_01_cro-0011-0143-g01.jpg
F1
Computed tomography (CT) and positron emission tomography revealed metastasis to the regional and right hilar lymph nodes (Fig. 1).
Computed tomography (CT) findings before radiotherapy. a Metastasis to the pretracheal lymph node at the level of the esophagus. b Right hilar lymphadenopathy at the level of the esophagus. c Gastric cardia (primary lesion). d No metastasis was visible in the para-aortic lymph node. e The radiotherapy dose distribution.
cro-0011-0143-g02.jpg
PMC5903152_01_cro-0011-0143-g02.jpg
F2
CT revealed constriction of the gastroesophageal junction (Fig. 2). To improve the dysphagia, palliative chemoradiotherapy with S-1 and 50.4 Gy in 28 fractions was administered in August 2017; the irradiation field included the hilar lymph node, gastric cardia (primary lesion), and regional lymph nodes (Fig. 2).
Clinical course following the administration of nivolumab. a Computed tomography (CT) findings upon completing radiotherapy; the tumor was still visible. b CT findings 14 days after the first administration of nivolumab; all lesions rapidly progressed.
cro-0011-0143-g03.jpg
PMC5903152_01_cro-0011-0143-g03.jpg
F3
CT findings before commencing nivolumab are shown in Figure 3a. CT performed 15 days following the first administration of nivolumab revealed rapid progression in the irradiation field (Fig. 3b).